# US 5,705,150 A · Antigen specific plasmacytomas and antibodies derived therefrom

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,705,150 A
- Document ID: US5705150A
- Status: Granted
- Kind: A
- Application number: 08/090,754
- Filed: 1993-07-13
- Granted: 1998-01-06
- Earliest claimed: 1990-05-04
- Assignees: The United States of America as represented by the Department of Health and Human Services; Wisconsin Alumni Research Foundation
- Inventors: Rex G. Risser, deceased; David A. Largaespada; Joseph F. Mushinski; Eva M. Weissinger; Harald Mishak
- Web page: https://patentgrep.com/patent/US5705150A

## CPC

- C12N 15/86: Viral vectors
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C12N 2740/13043: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed herein is a method for producing antibodies against an antigen of interest. Animal cells are exposed to both the antigen of interest and a recombinant retroviral vector. The vector contains a combination of oncogenes capable of inducing plasmacytomas. Plasmacytoma formation takes place rapidly and takes place in the presence of the antigen. A very high proportion of the plasmacytomas that are recovered are antigen specific.

## Claims

### Claim 1

A method for production of antibodies against a specified antigen, the method comprising:
immunizing a first murine host with an antigen to create immune responding B cells in the host;
removing the immune responding B cells from the first murine host;
transforming the immune responding B cells in vitro by introducing a vector comprising a myc oncogene and a vector comprising an abl oncogene into the cells; and
injecting the transformed cells into a second murine host in which the transformed cells can become established to form a plasmacytoma that produces antibodies against said antigen.

### Claim 2 (depends on 1)

The method of claim 1, wherein the myc oncogene is c-myc and the abl oncogene is v-abl.

### Claim 3 (depends on 1)

The method of claim 1, wherein the first murine host is injected with pristane following immunization.

### Claim 4 (depends on 1)

The method of claim 1, wherein the oncogenes are contained on the same retroviral vector.

### Claim 5 (depends on 1)

The method of claim 1, wherein the second murine host is injected with pristane prior to infecting said transformed cells into said second murine host.

### Claim 6 (depends on 1)

The method of claim 1, wherein the B cells are spleen cells.

### Claim 7 (depends on 1)

The method of claim 1, wherein the myc oncogene and the abl oncogene are introduced using a retroviral vector.

### Claim 8 (depends on 1)

The method of claim 1, wherein the myc oncogene and the abl oncogene are on a single recombinant vector.